Pharmacoeconomic analysis of oral therapies for onychomycosis: A US model

Clinical Therapeutics

Volumn 18, Issue 4, 1996, Pages 757-777

  Marchetti, Albert ^a   Piech, Catherine Tak ^b   McGhan, William F ^c   Neugut, Alfred I ^d   Smith, Brian T ^a  

^a Health Economics Research   (United States)

^b Sandoz Pharma Ltd   (Switzerland)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GRISEOFULVIN; ITRACONAZOLE; KETOCONAZOLE; TERBINAFINE;

ARTICLE; CANADA; CLINICAL TRIAL; COST; COST EFFECTIVENESS ANALYSIS; DECISION THEORY; DERMATOPHYTE; DRUG COST; EUROPE; FINGER NAIL; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; LABORATORY TEST; LIVER DYSFUNCTION; MODEL; ONYCHOMYCOSIS; ORAL DRUG ADMINISTRATION; PHARMACOECONOMICS; TOE; UNITED STATES; VERTIGO;

EID: 0029780839     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(96)80225-6     Document Type: Article

References (73)

1. Prevalence, morbidity and cost of dermatological diseases. J Invest Dermatol. 1979;75(P 2):395-401. Editorial.
2. Roberts DT. Prevalence of dermatophyte onychomycosis in the United Kingdom: Results of an omnibus survey. Br J Dermatol. 1992; 126:23-27.
3. Sais G, Jucgla A, Peyri J. Prevalence of dermatophyte onychomycosis in Spain: A cross sectional study. Br J Dermatol. 1995;132:758-761.
4. Summerbell RC, Kane J, Krajden S. Onychomycosis, tinea pedis, and tinea manuum caused by non-dermatophyte filamentous fungi. Mykosen. 1989;32:609-619.
5. Midgely G, Moore MK, Cook JC, et al. Mycology of nail disorders. J Am Acad Dermatol. 1994;31(Suppl):S68-S81.
6. Achten G, Wanet-Rouard J. Onychomycosis in the laboratory. Mycoses. 1978:21 (Suppl 1):124-127.
7. Al-Sogair SM, Moawad MK, Al-Humaidan YM. Fungal infection as a cause of skin disease in the eastern province of Saudi Arabia: Prevailing fungi and pattern of infection. Mycoses. 1991;34:333-337.
8. Clayton YM. Clinical and amycological diagnostic aspects of onychomycoses and dermatomycoses. Clin Exp Dermatol. 1992;17(Suppl 1):37-40.
9. Walshe MM, English MP. Fungi in nails. Br J Dermatol. 1966;78:198-207.
10. Lubeck DP, Patrick DL, McNulty P, et al. Quality of life of persons with onychomycosis. Qual Life Res. 1993;2:341-348.
11. Roseeuw D, DeDoncker P. New approaches to the treatment of onychomycosis. J Am Acad Dermatol. 1993;29: S45-S50.
12. Denning DW, Evans EGV, Kibbler CC, et al. Fungal nail disease: A good practice (report of a Working Group of the British Society for Medical Mycology). BMJ. 1995;311:1277-1281.
13. Sporanox®. Physicians' Desk Reference®. 50th ed. Montvale, NJ: Medical Economics Data, Inc; 1996:1305-1307.
14. Brodell RT, Elewski BE. Clinical pearl: Systemic antifungal drugs and drug interactions. J Am Acad Dermatol. 1995;33: 259-260.
15. Shear NH, Villars VV, Marsolais C. Terbinafine: An oral and topical antifungal agent. Clin Dermatol. 1992;9:487-495.
16. Arikian SR, Einarson TR, Kobelt-Nguyen G, et al. A multinational pharmacoeconomic analysis of oral therapies for onychomycosis. Br J Dermatol. 1994;130(Suppl 43): 35-44.
17. Halpern MT, Palmer C. Modeling the cost-effectiveness of oral therapy for nail fungus. Am J Managed Care. 1996;2:59-66.
18. 1995 Annual Medicare Physician Fee Schedule - Carrier File. Baltimore, Md: Health Care Finance Administration-Public Use Files, Empire New York Carrier; 1995.
19. 1995 Clinical Diagnostic Lab Fee Schedule - Carrier File. Baltimore, Md: Health Care Finance Administration-Public Use Files, Empire New York Carrier; 1995.
20. Snesil NR, ed. 1996 Red Book®. Montvale, NJ: Medical Economics Data, Inc; 1996.
21. Owens DK, Nease RF. Development of outcome-based practice guidelines: A method for structuring problems and synthesizing evidence. Joint Commission J Qual Improve. 1993;19:48-263.
22. Antman EM, Lau J, Kupelnick B, et al. A comparison of results of meta-analysis of randomized control trials and recommendations of clinical experts. Treatments of myocardial infarction. JAMA. 1992;268: 240-248.
23. Smith SW, Sealy DP, Schneider E, Lackland D. An evaluation of the safety and efficacy of fluconazole in the treatment of onychomycosis. South Med J. 1995;88: 1217-1220.
24. Takabayashi K, Nawata Y, Sumida T, et al. Effects of fluconazole on onychomycosis in the patients with collagen diseases. Ryumachi. 1995;35:72-76.
25. Nahass GR, Sisto M. Onychomycosis: Successful treatment with once-weekly fluconazole. Dermatology. 1993;186:59-61.
26. Coldiron B. Recalcitrant onychomycosis of the toenails successfully treated with fluconazole. Arch Dermatol. 1992;128: 909-910.
27. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-187.
28. Velanovich V. Meta-analysis for combining bayesian probabilities. Med Hypotheses. 1991;35:192-195.
29. Arenas R, Fernandez G, Dominguez L. Onychomycosis treated with itraconazole or griseofulvin alone with and without a topical antimycotic or keratolytic agent. Int J Dermatol. 1991;30:586-589.
30. Arenas R, Dominguez-Cherit J, Fernandez Luisa MA. Open randomized comparison of itraconazole versus terbinafine in onychomycosis. Int J Dermatol. 1995; 34:138-143.
31. Baudraz-Rosselet F, Rakosi T, Wili PB, Kenzelmann R. Treatment of onychomycosis with terbinafine. Br J Dermatol. 1992;126(Suppl 39):40-46.
32. Botter A, Nuijten ST. Further experiences with ketoconazole in the treatment of onychomycosis. Mykosen. 1981;24:156-166.
33. Brautigam M, Nolting S, Schopf RE, Weidinger G. Randomised double blind comparison of terbinafine and itraconazole for treatment of toenail tinea infection. BMJ. 1995;311:919-922.
34. Davies RR, Everall JD, Hamilton E. Mycological and clinical evaluation of griseofulvin for chronic onychomycosis. BMJ. 1967;3:464-468.
35. Estersohn H. An effective oral antifungal for chronic infections in the aged. J Am Podiatr Assoc. 1966;56:117-119.
36. Faergemann J, Anderson C, Hersle K, et al. Double-blind, parallel-group comparison of terbinafine and griseofulvin in the treatment of toenail onychomycosis. J Am Acad Dermatol. 1995;32:750-753.
37. Galimberti R, Negroni R, de Elias MRI, et al. The activity of ketoconazole in the treatment of onychomycosis. Rev Infect Dis. 1980;2:596-598.
38. Goldfarb NJ, Sulzberger MB. Experiences in 137 patients treated with oral griseofulvin. Arch Dermatol. 1960;81:838-840.
39. Goodfield MJD, Rowell NR, Forster RA, et al. Treatment of dermatophyte infection of the finger- and toe-nails with terbinafine (SF 86-327, Lamisil), an orally active fungicidal agent. Br J Dermatol. 1989; 121:753-757.
40. Goodfield MJD. Short-duration therapy with terbinafine for dermatophyte onychomycosis: A multicentre trial. Br J Dermatol. 1992;126(Suppl 39):33-35.
41. Goodfield MJD, Andrew L, Evans EGV. Short term treatment of dermatophyte onychomycosis with terbinafine. BMJ. 1992; 304:1151-1154.
42. Haneke E, Tausch I, Brautigam M, et al. Short-duration treatment of fingernail dermatophytosis: A randomized, double-blind study with terbinafine and griseofulvin. J Am Acad Dermatol. 1995;32:72-77.
43. Hay RJ, Clayton YM, Griffiths WAD, et al. A comparative double blind study of ketoconazole and griseofulvin in dermatophytosis. Br J Dermatol. 1985;112:691-696.
44. Hay RJ, Clayton YM. Treatment of chronic dermatophytosis and chronic oral candidosis with itraconazole. Rev Infect Dis. 1987;9(Suppl 1):S114-S118.
45. Hay RJ, Clayton YM, Moore MK, Midgely G. An evaluation of itraconazole in the management of onychomycosis. Br J Dermatol. 1988;119:359-366.
46. Hofmann H, Bautigam M, Weidinger G, et al. Treatment of toenail onychomycosis. A randomized, double-blind study with terbinafine and griseofulvin. Arch Dermatol. 1995;131:919-922.
47. Holub PG, Hubbard ER. Ketoconazole in the treatment of onychomycosis. J Am Podiatr Med Assoc. 1987;7:338-339.
48. Kaminsky A. Comparative effects of griseofulvin on onychomycosis and on psoriasis unguium. Arch Dermatol. 1960;18:838-840.
49. Kim JA, Ahn KJ, Kim JM, Youn JI. Efficacy and tolerability of itraconazole in patients with fingernail onychomycosis: A 6-week pilot study. Curr Ther Res. 1995;56:1066-1075.
50. Korting H, Schafer-Korting M, Zienicke H, et al. Treatment of tinea unguium with medium and high doses of ultramicrosize griseofulvin compared with that with itraconazole. Antimicrob Agents Chemother. 1993;37:2067-2068.
51. Lozano OW. Double-blind evaluation of ketoconazole in patients with onychomycosis. Mykosen. 1983;3:132-139.
52. Maibach HI, Kligman AM. Short-term treatment of onychomycosis with griseofulvin. Arch Dermatol. 1960;18:733-734.
53. Piepponen T, Blomqvist K, Brandt H, et al. Efficacy and safety of itraconazole in the long-term treatment of onychomycosis. J Antimicrob Chemother. 1992;29:195-205.
54. Quintaville P. Onychomycosis treated with ultrafine griseofulvin. J Am Podiatr Assoc. 1966;56:119-120.
55. Rakosi T. Terbinafine and onychomycosis. Dermatologica. 1990;181:174.
56. Robertson MH, Hanifin JM, Parker F. Oral therapy for dermatophyte infections unresponsive to griseofulvin. Rev Infect Dis. 1980;2:578-581.
57. Robertson MH, Rich P, Parker F, Hanifin JM. Ketoconazole in griseofulvin-resistant dermatophytosis. J Am Acad Dermatol. 1982;6:224-229.
58. Savin RC, Alton AV. Terbinafine in onychomycosis - a mini study. Int J Dermatol. 1993;32:918-919.
59. Svejgaard E. Oral ketoconazole as an alternative to griseofulvin in recalcitrant dermatophyte infections and onychomycosis. Acta Derm-Venereol Suppl. 1985; 65:143-149.
60. Symoens J, Moens M, Dom J, et al. An evaluation of two years of clinical experience with ketoconazole. Rev Infect Dis. 1980;2:674-691.
61. van der Schroeff JG, Cirkel PK, Crijns MB, et al. A randomized treatment duration-finding study of terbinafine in onychomycosis. Br J Dermatol. 1992;126 (Suppl 39):36-39.
62. Walsoe I, Stangerup M, Svejgaard E. Itraconazole in onychomycosis. Acta Derm-Venereol. 1990;70:137-140.
63. Willemsen M, De Doncker P, Willems J, et al. Posttreatment itraconazole levels in the nail. J Am Acad Dermatol. 1992; 26:731-735.
64. Zaias N, Serrano L. The successful treatment of finger Trichophyton rubrum onychomycosis with oral terbinafine. Clin Exp Dermatol. 1989;12:120-123.
65. Zaias N. Management of onychomycosis with oral terbinafine. J Am Acad Dermatol. 1990;23:810-812.
66. Data on file, Sandoz Pharmaceuticals Corporation, East Hanover, NJ, 1995.
67. Zaias N, Drachman D. A method for the determination of drug effectiveness in onychomycosis. J Am Acad Dermatol. 1983; 9:912-919.
68. Itraconazole prescribing information, Janssen Pharmaceutica Inc, Titusville, NJ.
69. Terbinafine prescribing information, Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
70. Villars VV, Jones TC. Special features of the clinical use of oral terbinafine in the treatment of fungal diseases. Br J Dermatol. 1992;126:61-69.
71. Einarson TR, Arikian SR, Doyle JJ. Rank order stability analysis (ROSA): Analyzing pharmacoeconomic data. Med Decis Mak. 1995;15:367-372.
72. De Doncker P, Decroix J, Pierard GE, et al. Antifungal pulse therapy for onychomycosis. A pharmacokinetic and pharmacodynamic investigation of monthly cycles of 1-week pulse therapy with itraconazole. Arch Dermatol. 1996;132: 34-41.
73. Davis R, Balfour JA. Terbinafine. A pharmacoeconomic evaluation of its use in superficial fungal infections. Pharmacoeconomics. 1995;8:253-269.